Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans. [electronic resource]
Producer: 20160401Description: 28-47 p. digitalISSN:- 1874-0758
- Administration, Oral
- Animals
- Biological Availability
- Biotransformation
- Bridged-Ring Compounds -- administration & dosage
- Cells, Cultured
- Cytochrome P-450 CYP3A -- metabolism
- Dealkylation
- Dogs
- Feces -- chemistry
- Hepatobiliary Elimination
- Hepatocytes -- metabolism
- Humans
- Janus Kinase 2 -- antagonists & inhibitors
- Liver -- metabolism
- Male
- Metabolic Clearance Rate
- Mice, Inbred BALB C
- Mice, Nude
- Microsomes, Liver -- metabolism
- Models, Biological
- Oxidation-Reduction
- Protein Binding
- Protein Kinase Inhibitors -- administration & dosage
- Pyrimidines -- administration & dosage
- Rats
- Rats, Wistar
- Species Specificity
- Tissue Distribution
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.